Port et al., 2010 - Google Patents
Activation of the Adrenergic Nervous System in Heart FailurePort et al., 2010
- Document ID
- 6199933383222125737
- Author
- Port J
- Sucharov C
- Bristow M
- Publication year
- Publication venue
- Heart Failure: A Companion to Braunwald's Heart Disease E-book
External Links
Snippet
In response to a variety of physiological and pathophysiological stresses, the need for increased cardiac myocardial performance is met by a commensurate increase in cardiac adrenergic drive. To facilitate this increase, norepinephrine (NE), the primary …
- 230000001800 adrenalinergic 0 title abstract description 49
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sierra et al. | The endocannabinoid system in cardiovascular function: novel insights and clinical implications | |
| Hafstad et al. | How exercise may amend metabolic disturbances in diabetic cardiomyopathy | |
| Cannavo et al. | Targeting cardiac β-adrenergic signaling via GRK2 inhibition for heart failure therapy | |
| Liu et al. | Cav1. 2 and Cav1. 3 L-type calcium channels regulate dopaminergic firing activity in the mouse ventral tegmental area | |
| Wang et al. | Contrasting inotropic responses to α1-adrenergic receptor stimulation in left versus right ventricular myocardium | |
| Joëls et al. | Corticosteroid effects on calcium signaling in limbic neurons | |
| Sekiguchi et al. | Therapeutic potential of RQ-00311651, a novel T-type Ca2+ channel blocker, in distinct rodent models for neuropathic and visceral pain | |
| Mittag et al. | Adaptations of the autonomous nervous system controlling heart rate are impaired by a mutant thyroid hormone receptor-α1 | |
| Abdulla et al. | The innervation of the kidney in renal injury and inflammation: a cause and consequence of deranged cardiovascular control | |
| Port et al. | Activation of the Adrenergic Nervous System in Heart Failure | |
| Rupp et al. | Metabolically-modulated growth and phenotype of the rat heart | |
| Wang et al. | Natural polysaccharides as potential anti-fibrotic agents: a review of their progress | |
| Sukhodub et al. | Nicotinamide-rich diet protects the heart against ischaemia–reperfusion in mice: a crucial role for cardiac SUR2A | |
| Gregor et al. | Medical treatment of hypertrophic cardiomyopathy–What do we know about it today? | |
| Ikeda et al. | Suppression of aldosterone synthesis and secretion by Ca2+ channel antagonists | |
| Kumari et al. | Dipeptidyl peptidase 4 (DPP4) inhibitors stride up the management of Parkinson's disease | |
| Kuwahara et al. | The organ-protective effect of N-type Ca2+ channel blockade | |
| Charalampopoulos et al. | Emerging pharmaceutical therapies in cardiopulmonary resuscitation and post-resuscitation syndrome | |
| Long et al. | An update on cardiovascular adrenergic receptor physiology and potential pharmacological applications in veterinary critical care | |
| Mattila et al. | The Effects of neuropeptide Y overexpression on the mouse model of doxorubicin-induced cardiotoxicity | |
| Aiba et al. | Adrenergic agonist induces rhythmic firing in quiescent cardiac preganglionic neurons in nucleus ambiguous via activation of intrinsic membrane excitability | |
| Bezerra et al. | Bezold–Jarisch reflex in sino-aortic denervated malnourished rats | |
| Kagota et al. | Abnormal amounts of intracellular calcium regulatory proteins in SHRSP. Z-Leprfa/IzmDmcr rats with metabolic syndrome and cardiac dysfunction | |
| Pappas et al. | Thyroid hormone modulates the responsiveness of rat aorta to [alpha] 1-adrenergic stimulation: an effect due to increased activation of [Beta] 2-adrenergic signaling | |
| Donato | What is the role of mineralocorticoids in vascular dysfunction? |